Biovail news

Biovail disappointed by clinical trial of its developmental drug for Parkinson?s disease psychosis

Biovail Announces Results from ACADIA's Phase III Trial of Pimavanserin in Parkinson's Disease Psychosis

BRIEF-Biovail says Acadia's phase 3 trial of Parkinson's drug misses primary endpoint

Maris, Defendant In SAC-Biovail Suit, Leaves Hedge Fund For Calyon

FINalternatives - 35 minutes ago
David Maris, a co-defendant of SAC Capital Advisors in pharmaceutical company Biovail's failed lawsuit against the hedge fund giant, is back on the sell-side. Maris has left his post as a ...

Analyst Sued by Biovail Joins Calyon

New York Times - 25 minutes ago
David Maris, the highly ranked pharmaceutical industry analyst whose bearish calls on Biovail became fodder for a lawsuit, is back in the sell-side stock picking business. Mr. Maris has joined ...

In Final Chapter of Biovail Saga, Paul Weiss Wins Dismissal of Claims Against Hedge Fund

Santhera and Biovail Enter into License Agreement to Develop and Commercialize JP-1730/Fipamezole in

Biovail's short selling lawsuit dismissed

BloggingStocks - 51 minutes ago
Judge Donald S. Goldman of the Superior Court of New Jersey dismissed Biovail's (NYSE: BVF) lawsuit against SAC Capital Advisors last week, saying that he lacked jurisdiction. Goldman wrote that ...

BenchmarkJournal.com Free Analyst Review for CMC, FLS, BVF, GSK, CZZ and SPF

SYS-CON Media - 51 minutes ago
LONDON -- (Marketwire) -- 08/24/09 -- Benchmark Journal brings independent company and sector research together, utilizing top financial advisors and investment tactics to provide you with a clear ...

Stockguru.com: Intelgenx Technologies Corp. is in the StockGuru Spotlight for August 24, 2009